Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Participants with Cholestatic Pruritus (EXPAND)
Maralixibat for Treatment of Cholestatic Pruritus (MRX-802 EXPAND)
Sponsor: Mirum Pharmaceuticals, Inc
Enrolling: Male and Female Patients
IRB Number: AAAV4711
U.S. Govt. ID: NCT06553768
Contact: Transplant Clinical Research Center: 212-305-3839 / tcrcstudyreferral@cumc.columbia.edu
Additional Study Information: The purpose of this study is to determine whether the investigational drug (maralixibat) is safe and effective in children and participants who have cholestatic liver disease with pruritus (itch) that has been responding to other therapies, and who have no other treatment options.If you have any questions regarding this study, please contact the Transplant Clinical Research Center (TCRC).
Investigator
Mercedes Martinez, MD
Do You Qualify?
Are you or your child at least 6 months of age? Yes No
Are you or your child experiencing pruritus (itch) due to liver disease? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Transplant Clinical Research Center
tcrcstudyreferral@cumc.columbia.edu
212-305-3839
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE